Page 3
Page 3
Drug discovery with privileged building Blocks : Tactics in medicinal chemistry
Drug Discovery with Privileged Building Blocks traces back PharmaBlock’s founding philosophy of designing privileged building blocks. High-quality building blocks are crucial not only to biological activities of different molecules but also to ADMET properties, which eventually will impact the success rate of drug discovery projects. A thorough study of how building blocks perform in drug molecules and a regular analysis of new building block structures in the latest researches have proven to be a fruitful strategy to generate novel building blocks. Using this strategy, PharmaBlock has supplied the drug industry with a great number of building blocks, which are increasingly being adopted by drug hunters, and these are identified in this book.
Drug discovery targeting drug-resistant bacteria
Drug Discovery Targeting Drug-Resistant Bacteria explores the status and possible future of developments in fighting drug-resistant bacteria. The book covers the majority of microbial diseases and the drugs targeting them. In addition, it discusses the potential targeting strategies and innovative approaches to address drug resistance. It brings together academic and industrial experts working on discovering and developing drugs targeting drug-resistant (DR) bacterial pathogens. New drugs active against drug-resistant pathogens are discussed, along with new strategies being used to discover molecules acting via new modes of action. In addition, alternative therapies such as peptides and phages are included.
Drug discovery and GBCR – Related CNS Disorders
Neurodegenerative diseases are a large group of neurological disorders with diverse etiological and pathological phenomena. However, current therapeutics rely mostly on symptomatic relief while failing to target the underlying disease pathobiology. G-protein-coupled receptors (GPCRs) are one of the most frequently targeted receptors for developing novel therapeutics for central nervous system (CNS) disorders. Many currently available antipsychotic therapeutics also act as either antagonists or agonists of different GPCRs. Therefore, GPCR-based drug development is spreading widely to regulate neurodegeneration and associated cognitive deficits through the modulation of canonical and noncanonical signals.
Drug Discovery and Evaluation : Safety and Pharmacokinetic Assays
This book is a landmark in the continuously changing world of drugs. It is essential reading for scientists and managers in the pharmaceutical industry who are involved in drug finding, drug development and decision making in the development process.
Drug discovery and development
Presents up-to-date scientific information for maximizing the ability of a multidisciplinary research team to discover and bring new drugs to the marketplace. It explores many scientific advances in new drug discovery and development for areas such as screening technologies, biotechnology approaches, and evaluation of efficacy and safety of drug candidates through preclinical testing. This book also greatly expands the focus on the clinical pharmacology, regulatory, and business aspects of bringing new drugs to the market and offers coverage of essential topics for companies involved in drug development. Historical perspectives and predicted trends are also provided.
Drug development for rare diseases
A disease is defined as rare if the prevalence is fewer than 200,000 in the United States. It is estimated that there are more than 7,000 rare diseases, which collectively affect 30 million Americans or 10% of the US population. This diverse and complex disease area poses challenges for patients, caregivers, regulators, drug developers, and other stakeholders. This book is proposed to give an overview of the common issues facing rare disease drug developers, summarize challenges specific to clinical development in small populations, discuss drug development strategies in the evolving regulatory environment, explain generation and utilization of different data and evidence
Drug development and approval process
Drug discovery is the process of identifying and characterizing molecules with the potential to safely modulate disease, with a goal to bring medicines that can improve the lives of patients. It is a lengthy and resource intensive process, that requires close cooperation across multiple disciplines. Optimizing the process of drug discovery is of great interest to the pharmaceutical industry, as the efficient identification and selection of suitable drug candidates can have a dramatic impact on the cost and profitability of new medicines.
Drug design : A conceptual overview
The newer research areas in pharmaceutical sciences, particularly molecular modeling and simulations, prompted a more efficient drug discovery process. Informatics integrated with pharmaceutical sciences (cheminformatics and bioinformatics) became an essential component of drug research. Drug informatics such as genomics and proteomics assists in the Rational Drug Design (RDD). This emerging discipline is known as “Computer-Aided Drug Design" (CADD), which has profound application in RDD. The advanced and adequate practice in drug design informatics is essential for pharmacy graduates. Hence, a companion for acquiring knowledge on these concepts is vital. The students of B. Pharmacy, M. Pharmacy (Pharmaceutical Chemistry, Pharmacology, and Pharmaceutics), biotechnology, biomedical engineering and other interdisciplinary fields may find this book as a reference guide.
Drug delivery via nasal route
Over the past 10 years, the interest in intranasal drug delivery has increased. The objective of this research is to summarize recent developments on intranasal administration for local and systemic delivery, as well as for CNS indications. Nasal delivery offers many advantages over standard systemic delivery systems, nevertheless, there are still formulation limitations and side effects to be optimized. Intranasal drug delivery in the field of drug development is an interesting delivery route for the treatment of neurological disorders. Systemic approaches often fail to efficiently supply the CNS with drugs. This research describes the anatomical, histological and physiological basis and summarizes currently approved drugs for administration via intranasal delivery. Further, the research focuses on advantages and disadvantages of intranasal applied compounds and discusses formulation aspects that need to be considered for drug development.
Drug Delivery Approaches : Perspectives from Pharmacokinetics and Pharmacodynamics
Delivers a thorough discussion of drug delivery options to achieve target profiles and approaches as defined by physical and pharmacokinetic models. The book offers an overview of drug absorption and physiological models, chapters on oral delivery routes with a focus on both PBPK and multiple dosage form options. It also provides an explanation of the pharmacokinetics of the formulation of drugs delivered by systemic transdermal routes.
Dose Finding in Drug Development
When you go to the pharmacy and fill a prescription, have you ever wondered if the dose of the medication is right for you? Can the dose be too low so that the drug will not work? This book answers some of these questions, and introduces the drug development process, the design and analysis of clinical trials.
Dipeptidyl Aminopeptidases : Basic Science and Clinical Applications
Dipeptidyl Aminopeptidases exert a potent modulatory role at an interface between immune mechanisms, metabolic responses, and neuroendocrine pathways. Experimental models and clinical studies addressing the role of these enzymes and the effect of specific inhibitors pave the way to novel therapeutic concepts in immunology, rheumatology, oncology, reproductive medicine and diabetes. Leading experts in the field will contribute to this book, which will present a state-of-the-art view on these enzymes at a time when our understanding of their function is growing ever more rapidly and therapeutic options have become imminent. The sections of the book will focus on various topics including DP IV and related enzymes in: expression and function, metabolic disorders, immune mechanisms and immune disorders, neuronal diseases and cancer, and related drug development.
Dictionary of Pharmaceutical Medicine
Defines various terms typically used in pharmaceutical medicine. A new, 4th edition includes adaptations of the text to the steadily increasing regulatory requirements, particularly in the area of genetics/gene therapy, product quality (e.g., protection against falsified medicines) and of product safety (pharmacovigilance). Further evolving areas that are covered by the 4th edition are typical “grey zones” (health effects often borderline to medicinal products) such as cosmetics and dietary supplements where misleading information is prohibited on one hand but where any health claims need formal authorisation on the other.
Data science, AI, and machine learning in drug development
The confluence of big data, AI, and machine learning has led to a paradigm shift in how innovative medicines are developed and healthcare delivered. To fully capitalize on these technological advances, it is essential to systematically harness data from diverse sources and leverage digital technologies and advanced analytics to enable data-driven decisions. Data science stands at a unique moment of opportunity to lead such a transformative change. Intended to be a single source of information, Data Science, AI, and Machine Learning in Drug Research and Development covers a wide range of topics on the changing landscape of drug R&D, emerging applications of big data, AI and machine learning in drug development, and the build of robust data science organizations to drive biopharmaceutical digital transformations
Contemporary Accounts in Drug Discovery and Development
Drug discovery is a lengthy and complex process that typically involves identifying an unmet medical need, determining a biological target, chemical library screening to identify a lead, chemical optimization, preclinical studies and clinical trials. This process often takes many years to complete, and relies on practitioners’ knowledge of chemistry and biology, but also—and perhaps more importantly—on experience. Improving the success rate in discovery and development through a thorough knowledge of drug discovery principles and advances in technology is critical for advancement in the field.
Conditional Mutagenesis : An Approach to Disease Models
Leading experts provide timely and comprehensive information on methods for conditional mutagenesis in the mouse (part 1) and their application to model human physiology and pathophysiology (part 2). It illustrates how sophisticated genetic manipulations of the mouse genome are employed to model human diseases and to identify underlying molecular mechanisms. Finally the book considers the development of new drugs to treat them.
Concepts in pharmaceutical biotechnology and drug development
Provides comprehensive coverage of the development of new pharmaceuticals and the enhancement of existing ones. It offers a comprehensive understanding of pharmaceutical biotechnology, including its underlying principles and practical applications from an industrial standpoint. While introducing the roles and applications of biotechnology in drug design and development, the book describes how developments in other fields, like genomics, proteomics, and high-throughput screening, have facilitated the discovery of novel therapeutic targets and drug development methods. It included concepts that are essential to biotechnology and apply to protein therapies. And provides a thorough overview of the ways in which biotechnology influences drug development, production, and regulation, and is a valuable resource for those seeking to enhance their understanding in this area.
Computational drug discovery and design
Provides new and updated methods and techniques for identification of drug target, binding sites prediction, high- throughput virtual screening, lead discovery and optimization, conformational sampling, prediction of pharmacokinetic properties using computer-based methodologies. Chapters also focus on the application of the latest artificial intelligence technologies for computer aided drug discovery.
Leading Pharmaceutical Innovation : Trends and Drivers for Growth in the Pharmaceutical Industry
Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. Our findings are illustrated by cases from Europe, the US, and Asia.
Clinical biochemistry and drug development : From fundamentals to output
Focuses on clinical biochemistry fundamentals, cell culture techniques, and drug discovery and development concepts. It deals with three different fields of clinical research: cell culture, clinical biochemistry, and drug discovery and development.
